Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines

Martin K. Hunn, Ian F. Hermans

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)


Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigenpresenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications.

Original languageEnglish
Article numbere23789
Number of pages3
Issue number4
Publication statusPublished - 1 Apr 2013
Externally publishedYes


  • α-galactosylceramide
  • Cancer vaccine
  • Dendritic cell
  • Glioblastoma multiforme
  • Glioma
  • NKT cell

Cite this